ABIGAIL L OLIVER

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family AUGUSTA, KS NPI 1700218914

General Payments — all program years on this page

$1,768.20

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 119
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $335.18 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $335.1818

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Astellas Pharma US Inc $98.015
Novo Nordisk AS $87.355
ABBVIE INC. $44.742
ARGENX US, INC. $35.012
Acerta Pharma LLC $32.222
Abbott Laboratories $23.501
E.R. Squibb & Sons, L.L.C. $14.351

By program year

Program yearAmountRecords
2021 $732.8752
2022 $430.5933
2023 $269.5616
2024 $335.1818

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1100288594 Novo Nordisk Inc $17.85 06/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100411032 Novo Nordisk Inc $18.44 10/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100439401 Novo Nordisk Inc $16.98 03/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100529227 Novo Nordisk Inc $18.14 03/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100614889 Novo Nordisk Inc $15.94 04/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101251842 E.R. Squibb & Sons, L.L.C. $14.35 02/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104457066 AstraZeneca Pharmaceuticals LP $15.91 08/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105680477 AstraZeneca Pharmaceuticals LP $16.31 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107761078 ABBVIE INC. $18.85 05/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107761080 ABBVIE INC. $25.89 09/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125207388 Abbott Laboratories $23.50 12/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139467768 Astellas Pharma US Inc $20.32 01/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139486624 Astellas Pharma US Inc $18.76 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139494680 Astellas Pharma US Inc $17.41 04/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139513585 Astellas Pharma US Inc $17.41 06/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139518089 Astellas Pharma US Inc $24.11 08/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142155571 ARGENX US, INC. $17.91 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142155847 ARGENX US, INC. $17.10 11/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.